PMID- 26637883
OWN - NLM
STAT- MEDLINE
DCOM- 20160428
LR  - 20151206
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 35
IP  - 12
DP  - 2015 Dec
TI  - Effects of Cabazitaxel in Renal Cell Carcinoma Cell Lines.
PG  - 6671-7
AB  - BACKGROUND/AIM: Advanced renal cell carcinoma is treated with mammalian target of 
      rapamycin (mTOR) inhibitors or tyrosine kinase inhibitors (TKIs). The effects of 
      these drugs are, however, limited and novel treatment strategies are required. 
      Clear-cell type renal cell carcinoma (ccRCC) is chemo-resistant, in part, due to 
      expression of multidrug resistance proteins such as p-glycoprotein. Cabazitaxel, 
      a tubulin-binding taxane drug used for castration-resistant prostate cancer, has 
      less affinity for p-glycoprotein compared to docetaxel. In the current study, the 
      effects of docetaxel and cabazitaxel on ccRCC cells were investigated. MATERIALS 
      AND METHODS: The expression of p-glycoprotein was evaluated in the ccRCC cell 
      lines, Caki-1, KMRC-1 and OS-RC-2 by western blotting. Cells were treated with 
      cabazitaxel or docetaxel, and growth kinetics and tubulin polymerization were 
      determined by the WST-1 assay and cell-based tubulin polymerization assay, 
      respectively. Intracellular drug concentrations were measured by chromatography. 
      AKT activation after treatment was examined by western blotting. RESULTS: All 
      ccRCC cell lines expressed p-glycoprotein. Cabazitaxel inhibited cell growth and 
      induced tubulin polymerization more potently than docetaxel. The intracellular 
      concentration of cabazitaxel was much higher than docetaxel in all cell lines. 
      Both docetaxel and cabazitaxel inhibit AKT phosphorylation at 5 min among three 
      cells. CONCLUSION: Cabazitaxel inhibits growth of ccRCC cells expressing 
      p-glycoprotein and could thus be possibly used for advanced ccRCC patients in 
      combination with targeted-therapy enhancing their effects.
CI  - Copyright(c) 2015 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - Mizutani, Kosuke
AU  - Mizutani K
AD  - Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan 
      mizutech@gifu-u.ac.jp.
FAU - Tomoda, Masashi
AU  - Tomoda M
AD  - Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
FAU - Ohno, Yuta
AU  - Ohno Y
AD  - Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
FAU - Hayashi, Hideki
AU  - Hayashi H
AD  - Department of Pharmacy, Gifu University Hospital, Gifu, Japan Laboratory of 
      Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, 
      Japan.
FAU - Fujita, Yasunori
AU  - Fujita Y
AD  - Research Team for Mechanism of Aging, Tokyo Metropolitan Institute of Gerontology 
      Itabashi-ku, Tokyo, Japan.
FAU - Kawakami, Kyojiro
AU  - Kawakami K
AD  - Research Team for Mechanism of Aging, Tokyo Metropolitan Institute of Gerontology 
      Itabashi-ku, Tokyo, Japan.
FAU - Kameyama, Koji
AU  - Kameyama K
AD  - Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
FAU - Kato, Taku
AU  - Kato T
AD  - Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
FAU - Sugiyama, Tadashi
AU  - Sugiyama T
AD  - Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical 
      University, Gifu, Japan.
FAU - Itoh, Yoshinori
AU  - Itoh Y
AD  - Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
FAU - Ito, Masafumi
AU  - Ito M
AD  - Research Team for Mechanism of Aging, Tokyo Metropolitan Institute of Gerontology 
      Itabashi-ku, Tokyo, Japan.
FAU - Deguchi, Takashi
AU  - Deguchi T
AD  - Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Taxoids)
RN  - 51F690397J (cabazitaxel)
SB  - IM
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Humans
MH  - Taxoids/administration & dosage/*therapeutic use
OTO - NOTNLM
OT  - AKT
OT  - Caki-1
OT  - KMRC-1
OT  - OS-RC-2
OT  - Renal cell carcinoma
OT  - cabazitaxel
OT  - docetaxel
OT  - p-glycoprotein
EDAT- 2015/12/08 06:00
MHDA- 2016/04/29 06:00
CRDT- 2015/12/06 06:00
PHST- 2015/12/06 06:00 [entrez]
PHST- 2015/12/08 06:00 [pubmed]
PHST- 2016/04/29 06:00 [medline]
AID - 35/12/6671 [pii]
PST - ppublish
SO  - Anticancer Res. 2015 Dec;35(12):6671-7.